BioBiz Buzz
BioBiz Buzz
Podcast Description
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. Disclaimerhttps://biobizbuzz.com/disclaimer/
Podcast Insights
Content Themes
The podcast focuses on biotechnology, pharmaceuticals, and medical technology, with episodes highlighting significant themes like scientific advancements, emerging technologies, and market trends. Examples include the novel ED treatment with Dicot Pharma's LIB-01, Cereno Scientific's epigenetic approaches to rare cardiovascular diseases, and innovations in CRISPR technology with Caszyme.
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
What if an annual self-injection could silence your hidden cardiac risk instead of just lowering your LDL?
In this episode of BioBiz Buzz, Mike Ward sits down with David Solomon, CEO of Thalia Therapeutics, to unpack how a once-yearly RNA gene-silencing therapy targeting both lipoprotein(a) and PCSK9 could finally tackle the stubborn burden of coronary artery disease, stroke and cardiac arrest that persists despite widespread statin use.
You’ll hear how Thalia is exploiting patent white space around dual-target constructs, why evolution turned Lp(a) from a survival mechanism into a modern liability, and how growing regulatory comfort with siRNA could allow a fast jump from non-human primate data into pivotal trials.
Solomon also lays out his playbook for turning a rebranded AIM-listed micro-cap into Europe’s RNA therapeutics champion, from pipeline building and delivery innovation to early big pharma partnerships and a potential future tilt at NASDAQ.
● Feedback
● Subscribe (Get notified when new episodes are available. NO marketing!)
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.